Komentarz
Article Sidebar
Published:
Jun 30, 2015
Main Article Content
Abstract
None
Article Details
How to Cite
Grabowski , M. (2015). Komentarz. Medycyna Faktow (J EBM), 8(2(27), 20-21. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2306
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zugck Ch., Martinka P., Stockl G.: Ivabradine treatment in chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Advances in Therapy 2014; 31(9): 961-974.
2. Volterrani M., Cice G., Caminiti G. et al.: Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). International Journal of Cardiology 2011; 151(2): 218-224.
3. Bagriy A.E., Schukina E.V., Samoilova O.V. et al.: Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Advances in Therapy 2015; 32(2): 108-119.
4. Setoguchi S., Stevenson L.W., Schneeweiss S.: Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal 2007; 154(2): 260-266.
5. Grabowski M.: 12 powodów, dla których warto zastosować iwabradynę w terapii niewydolności serca. Medycyna Faktów 2015; 26(1): 25-33.
2. Volterrani M., Cice G., Caminiti G. et al.: Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). International Journal of Cardiology 2011; 151(2): 218-224.
3. Bagriy A.E., Schukina E.V., Samoilova O.V. et al.: Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study. Advances in Therapy 2015; 32(2): 108-119.
4. Setoguchi S., Stevenson L.W., Schneeweiss S.: Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal 2007; 154(2): 260-266.
5. Grabowski M.: 12 powodów, dla których warto zastosować iwabradynę w terapii niewydolności serca. Medycyna Faktów 2015; 26(1): 25-33.